NCT00675844View on ClinicalTrials.gov

An Open-Label Treatment Protocol to Provide Continued Elvucitabine Treatment

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

March 31, 2010

Study Completion Date

March 31, 2010

Conditions
HIV Infections
Interventions
DRUG

Elvucitabine

10 milligrams (mg) elvucitabine daily as part of an ART regimen

Trial Locations (5)

32504

Clinical Trial Site, Pensacola

32803

Clinical Trial Site, Orlando

75204

Clinical Trial Site, Dallas

78705

Clinical Trial Site, Austin

07102

Clinical Trial Site, Newark

Sponsors
All Listed Sponsors
collaborator

Achillion, a wholly owned subsidiary of Alexion

INDUSTRY

lead

Alexion Pharmaceuticals, Inc.

INDUSTRY